ENLV
Enlivex Therapeutics Ltd.NASDAQHealthcare$0.95-8.24%ClosedMarket Cap: $23.1M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
0.02
PEG
0.00
P/B
0.02
P/S
0.00
EV/EBITDA
-1.39
DCF Value
$-0.04
FCF Yield
-52.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
248.1%
ROA
53.1%
ROIC
-0.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $1.24B | $25.79 |
| FY 2025 | $0.00 | $1.24B | $25.48 |
| Q3 2025 | $0.00 | $-2.2M | $-0.09 |
| Q2 2025 | $0.00 | $-1.9M | $-0.08 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2026-01-12D. Boral CapitalHold
2025-11-24D. Boral CapitalBuy
2025-10-29D. Boral CapitalBuy
2025-09-26HC Wainwright & Co.Buy
2025-09-02Trading Activity
Insider Trades
View AllHershkovitz Orenofficer: Chief Executive Officer
SellWed Mar 18
Hershkovitz Orenofficer: Chief Executive Officer
SellWed Mar 18
Hershkovitz Orenofficer: Chief Executive Officer
SellWed Mar 18
Shlosberger Shacharofficer: Chief Financial Officer
SellWed Mar 18
Shlosberger Shacharofficer: Chief Financial Officer
SellWed Mar 18
Company Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
1.68
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.